MXPA04002449A - Cristales de derivado de hidroxinorefedrina. - Google Patents

Cristales de derivado de hidroxinorefedrina.

Info

Publication number
MXPA04002449A
MXPA04002449A MXPA04002449A MXPA04002449A MXPA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A
Authority
MX
Mexico
Prior art keywords
crystals
ethyl
hydroxynorephedrine
derivative
hydroxynorephedrine derivative
Prior art date
Application number
MXPA04002449A
Other languages
English (en)
Spanish (es)
Inventor
Harada Hiromu
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MXPA04002449A publication Critical patent/MXPA04002449A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MXPA04002449A 2001-09-13 2002-08-27 Cristales de derivado de hidroxinorefedrina. MXPA04002449A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001277345 2001-09-13
PCT/JP2002/008596 WO2003024916A1 (fr) 2001-09-13 2002-08-27 Cristaux d'un derive d'hydroxynorephedrine

Publications (1)

Publication Number Publication Date
MXPA04002449A true MXPA04002449A (es) 2004-07-23

Family

ID=19101883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002449A MXPA04002449A (es) 2001-09-13 2002-08-27 Cristales de derivado de hidroxinorefedrina.

Country Status (29)

Country Link
US (1) US7208520B2 (ja)
EP (1) EP1426355B1 (ja)
JP (1) JP4157036B2 (ja)
KR (2) KR20080098691A (ja)
CN (1) CN1275936C (ja)
AT (1) ATE411276T1 (ja)
AU (1) AU2002330453B2 (ja)
BR (1) BR0212494A (ja)
CA (1) CA2458544C (ja)
CO (1) CO5560555A2 (ja)
CY (1) CY1109409T1 (ja)
DE (1) DE60229404D1 (ja)
DK (1) DK1426355T3 (ja)
EA (1) EA006022B1 (ja)
EC (1) ECSP045017A (ja)
ES (1) ES2314092T3 (ja)
HK (1) HK1070051A1 (ja)
HR (1) HRP20040250A2 (ja)
HU (1) HUP0401694A3 (ja)
IL (2) IL160681A0 (ja)
MX (1) MXPA04002449A (ja)
NO (1) NO328252B1 (ja)
NZ (1) NZ531602A (ja)
PL (1) PL206246B1 (ja)
PT (1) PT1426355E (ja)
SI (1) SI1426355T1 (ja)
UA (1) UA77000C2 (ja)
WO (1) WO2003024916A1 (ja)
ZA (1) ZA200401757B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ATE401878T1 (de) * 2003-05-05 2008-08-15 Kissei Pharmaceutical Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
EP1682183A2 (de) * 2003-11-03 2006-07-26 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−3アゴニストの使用
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
JP2008517886A (ja) 2004-10-26 2008-05-29 キッセイ薬品工業株式会社 フェノキシ酢酸誘導体の合成
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
JPWO2006118087A1 (ja) * 2005-04-26 2008-12-18 キッセイ薬品工業株式会社 ヒドロキシノルエフェドリン誘導体塩酸塩・1/4水和物の結晶
EP1878719A4 (en) * 2005-04-26 2010-10-06 Kissei Pharmaceutical HYDROXYNOREPHEDRINE DERIVATIVE HYDROCHLORIDE POLYMORPH CRYSTAL
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
CA2695634C (en) 2007-08-06 2018-01-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
DK3225250T3 (da) 2008-05-21 2019-11-04 Ferring Bv Orodispersibel desmopressin til forlængelse af den indledende søvnperiode, som ikke forstyrres af nykturi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
JP4005730B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005729B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005731B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体の結晶多形

Also Published As

Publication number Publication date
BR0212494A (pt) 2004-08-24
HUP0401694A2 (hu) 2004-11-29
ZA200401757B (en) 2005-03-03
KR20040044881A (ko) 2004-05-31
PL206246B1 (pl) 2010-07-30
CA2458544A1 (en) 2003-03-27
US7208520B2 (en) 2007-04-24
CA2458544C (en) 2010-08-17
DK1426355T3 (da) 2009-02-23
NZ531602A (en) 2006-01-27
PT1426355E (pt) 2008-11-03
HUP0401694A3 (en) 2008-03-28
JPWO2003024916A1 (ja) 2004-12-24
NO20041060L (no) 2004-06-11
CN1275936C (zh) 2006-09-20
ECSP045017A (es) 2004-09-27
WO2003024916A1 (fr) 2003-03-27
UA77000C2 (en) 2006-10-16
US20040242686A1 (en) 2004-12-02
CN1553890A (zh) 2004-12-08
EA200400311A1 (ru) 2004-08-26
IL160681A0 (en) 2004-08-31
CO5560555A2 (es) 2005-09-30
KR100874952B1 (ko) 2008-12-19
ES2314092T3 (es) 2009-03-16
ATE411276T1 (de) 2008-10-15
PL367874A1 (en) 2005-03-07
HK1070051A1 (en) 2005-06-10
CY1109409T1 (el) 2014-07-02
DE60229404D1 (de) 2008-11-27
AU2002330453B2 (en) 2008-04-17
HRP20040250A2 (en) 2005-02-28
NO328252B1 (no) 2010-01-18
SI1426355T1 (sl) 2009-02-28
IL160681A (en) 2010-06-16
EP1426355A4 (en) 2006-03-29
EP1426355B1 (en) 2008-10-15
EP1426355A1 (en) 2004-06-09
EA006022B1 (ru) 2005-08-25
KR20080098691A (ko) 2008-11-11
JP4157036B2 (ja) 2008-09-24

Similar Documents

Publication Publication Date Title
MXPA04002449A (es) Cristales de derivado de hidroxinorefedrina.
GEP20043238B (en) Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
EP2161265A3 (en) Compounds having selective inhibiting effect at GSK3
AU7071096A (en) Peripherally active anti-hyperalgesic opiates
AR033542A1 (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamicos
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
RU2000126841A (ru) Производные амида и антагонисты ноцицептина
WO2002089782A3 (en) Dioxanes and uses thereof
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
KR900011724A (ko) 특정 피롤릴페닐-치환된 하이드록삼산 유도체
SE9900190D0 (sv) New compounds
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
EP0372941A3 (en) Anti-inflammatory 5-hydroxy-2-furanones
WO2003018564A1 (fr) Inhibiteur d'acat selectif de la paroi vasculaire
DE60300683D1 (de) Prucaloprid-n-oxid
RU2005137701A (ru) Применение производных феноксиуксусной кислоты для лечения гиперактивности мочевого пузыря
WO2023235837A3 (en) 4-(3h-pyrazolo[4,3-f]quinolin-7-yl)-n-(2-(dimethylamino)ethyl)benzamide- or hydroxamic acid compounds, compositions, and methods of use
WO2003032974A3 (en) Use of sulfonamide derivatives as pharmaceuticals compounds
RU2001104896A (ru) Производные фенилового эфира альфа-аминокислоты
US20080140450A1 (en) Treatment of metabolic syndrome with norfluoxetine
RU2004109224A (ru) Соединения циклического амина

Legal Events

Date Code Title Description
FG Grant or registration